Compare · DRTS vs DXCM
DRTS vs DXCM
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 34.2x DRTS ($822.9M).
- Over the past year, DRTS is up 198.4% and DXCM is down 10.2% - DRTS leads by 208.6 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 10 for DRTS).
- DXCM has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Alpha Tau Medical Ltd.
- DexCom Inc.
- Price
- $9.34-0.21%
- $76.97+5.66%
- Market cap
- $822.9M
- $28.11B
- 1M return
- +19.06%
- +26.28%
- 1Y return
- +198.40%
- -10.16%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 10
- 26
- Recent ratings
- 7
- 25
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DRTS
- Chief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
- Barclays initiated coverage on Alpha Tau with a new price target
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Alpha Tau to Participate in May Investor Conferences
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)